Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Purified inactivated rabies vaccine · 1 trial · 2 indications
Rabies virus neutralizing antibody (RVNA) titer as determined by rapid fluorescent focus inhibition test (RFFIT)
| Arm | Type | Description |
|---|---|---|
| VRVg Vaccine Group 1 | EXPERIMENTAL | Participants aged 18 years or older will receive Purified Vero Rabies Vaccine Serum Free (VRVg) |
| VRVg Vaccine Group 2 | EXPERIMENTAL | Participants aged 10 to 17 years will receive Purified Vero Rabies Vaccine Serum Free (VRVg) |
| Verorab Vaccine Group 1 | ACTIVE_COMPARATOR | Participants aged 18 years or older will receive Verorab Vaccine |
| Verorab Vaccine Group 2 | ACTIVE_COMPARATOR | Participants aged 10 to 17 years will receive Verorab Vaccine |
| Name | Type | Description |
|---|---|---|
| Purified inactivated rabies vaccine, serum free | BIOLOGICAL | 0.5 mL, Intramuscular |
| Purified Vero Rabies Vaccine | BIOLOGICAL | 0.5 mL, Intramuscular |
Inclusion Criteria: Adults (≥ 18 years) * Aged ≥ 18 years on the day of inclusion * Informed consent form has been signed and dated * Able to attend all scheduled visits and to comply with all trial procedures * For a woman of childbearing potential, use of an effective method of contraception or ...
The purified inactivated rabies vaccine is used for immunization against rabies, a viral infection that affects the nervous system. It is being developed by Sanofi as a serum-free vaccine candidate for rabies prevention. The vaccine is intended to protect people from rabies virus infection.
Sanofi, which trades under the ticker SNY, is the developer of the purified inactivated rabies vaccine. Sanofi is a global pharmaceutical company, and this serum-free rabies vaccine candidate is part of its vaccine portfolio. The company conducted the clinical development of this vaccine in China.
The purified inactivated rabies vaccine is in Phase 3 clinical development. It is an investigational vaccine candidate and is not approved. The Phase 3 trial has been completed, and the vaccine remains in clinical development for rabies prevention.
The purified inactivated rabies vaccine was studied in a completed Phase 3 trial, NCT01339312, titled Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine. The trial enrolled 816 participants in China, was randomized, double blind, and active controlled, and included healthy volunteers aged 10 years and older.
Yes. The purified inactivated rabies vaccine is also known as the purified inactivated rabies vaccine, serum free. These names refer to the same Sanofi vaccine candidate, which is a serum-free formulation being developed for rabies prevention. The serum-free designation describes the formulation used in its clinical development.
The purified inactivated rabies vaccine is a vaccine that uses inactivated rabies virus to stimulate an immune response against rabies. It is a serum-free formulation, meaning it does not contain serum components. The vaccine is designed to prompt the body to develop protection against rabies virus infection.